3 results
Approved WMOPending
To establish the MaximumTolerated Dose, Dose Limiting Toxicities, and the safety profile of BMS-833923 administered in combination with cisplatin and capecitabine as first-line therapy. To describe preliminary evidence of tumor response as measured…
Approved WMOCompleted
The primary study objective is to compare the rate of major CIED infections through 12-months post-implant between the TYRX envelope group and the control group.
Approved WMORecruiting
The primary objective of the study is to describe the pharmacokinetics of Nivolumab (how quickly it is absorbed by the body) when injected under the skin (subcutaneously) with or without rHuPH20. rHuPH20 is an enzyme that can increase the absorption…